Answers are grounded in this paper and cite their sources.
Background Genitourinary syndrome of menopause (GSM) is a chronic condition resulting from oestrogen deficiency and characterised by persistent genital, sexual, and urinary symptoms that can substantially impair quality of life. While local oestrogen therapy is highly effective, a significant proportion of women are unable or unwilling to use hormonal treatments, highlighting the need for effective non‐hormonal options. Objective This narrative review examines local, non‐hormonal approaches to GSM, with a particular emphasis on injectable hyaluronic acid‐based therapies. Main Findings Hyaluronic acid is integral to tissue hydration, viscoelasticity, and the maintenance of extracellular matrix integrity, processes that are compromised in GSM. Topical formulations are commonly used to provide surface hydration and symptom relief, while injectable approaches deliver hyaluronic acid to deeper tissue layers; the potential implications for the magnitude and duration of clinical benefit require further evaluation. Among injectable formulations, hybrid cooperative complex hyaluronic acid (HCC‐HA) has been evaluated in small prospective studies and one randomised trial in women with sexual dysfunction rather than strictly defined GSM. Available studies report potential improvements in some symptoms, including vaginal dryness and dyspareunia. However, improvements were not demonstrated across all assessed outcomes, including certain sexual‐function and quality‐of‐life measures. No serious adverse events were reported in the available studies, although larger studies with longer follow‐up are needed to characterise the safety profile more fully. Conclusions Injectable hyaluronic acid‐based therapies are emerging non‐hormonal interventions for vulvovaginal symptoms associated with GSM. Current evidence does not yet establish their role as routine or guideline‐recommended treatments. This evidentiary position should be considered separately from the intended purpose and regulatory status of individual devices. Larger independent trials, longer‐term safety data, and health‐economic evaluations are needed to define their comparative clinical role.
No takes yet. Share an insight, caveat, or question.
Menabrito et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: